{"id":"cmab008","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a monoclonal antibody developed by Shanghai Biomabs, CMAB008 is designed to modulate immune responses or block tumor survival pathways. The exact molecular target requires confirmation, but the drug is in Phase 3 development, suggesting clinical efficacy has been demonstrated in earlier trials for its intended oncology indication.","oneSentence":"CMAB008 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:29.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05906576","phase":"PHASE4","title":"Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients","status":"RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2023-09-21","conditions":"Crohn Disease","enrollment":30},{"nctId":"NCT04779892","phase":"PHASE1","title":"The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety","status":"COMPLETED","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2020-02-01","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT03478111","phase":"PHASE3","title":"CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-03-30","conditions":"Rheumatoid Arthritis","enrollment":390}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["infliximab"],"phase":"phase_3","status":"active","brandName":"CMAB008","genericName":"CMAB008","companyName":"Shanghai Biomabs Pharmaceutical Co., Ltd.","companyId":"shanghai-biomabs-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}